Le Lézard
Classified in: Health, Science and technology
Subject: BFA

XRHealth Receives Patent to Utilize Approaches that Incorporate Biofeedback in Virtual Reality and Augmented Reality Therapy


BOSTON, Sept. 15, 2020 /PRNewswire/ -- XRHealth, the leader in extended reality therapeutic applications, announces that they received a patent to utilize approaches that incorporate biofeedback into their extended reality therapy.  These novel approaches enable VR/AR therapy to address patient pain based on biofeedback such us heart rate variability, EEG, galvanic skin response, and other critical responses while patients are using the VR/AR devices.  Solutions that incorporate biofeedback allow patient treatment to be customized according to their unique needs and better inform clinicians on how patients are responding to therapy.

XRHealth plans to incorporate their VR/AR therapy with the Apple Watch, specifically since the watch has advanced features including a medical grade, FDA-cleared electrocardiogram (EKG) that measures heartbeat. XRHealth will use the output measurements of the Apple Watch to detect pain, which will modify VR/AR therapy treatment for patients based on the pain that they feel during the sessions.

"The newly awarded patent reflects XRHealth's commitment to creating the most sophisticated form of therapy that responds to patient physical needs in real-time," said Eran Orr, CEO of XRHealth. "Virtual Reality therapy that incorporates biofeedback will enhance and personalize the patient experience and provide clinicians with critical insights." 

U.S. Patent No. 16/067,480, entitled "A Therapy and Physical Training Device," was issued on September 15, 2020. 

XRHealth created the first virtual reality telehealth clinic in the world that treats multiple conditions like anxiety & stress, cognitive impairment, pain management, Parkinson's, and multiple sclerosis. XRHealth provides doctors with patient data that allows them to monitor and treat them in real-time.

About XRHealth:

XRHealth, is the leader in extended reality therapeutic applications providing both VR and AR solutions for the medical industry. XRHealth is the first certified Extended Reality medical company in the world; their Medical Applications are FDA & CE Registered. They provide first-of-its-kind healthcare technology that helps clinicians better manage their patients' care via specialized extended reality technology solutions and data analysis. XRHealth created the first virtual reality telehealth clinic in the world that utilizes the VRHealth Platform that collects and examines user data through artificial intelligence (AI) and cloud-computing algorithms to deliver advanced data analytics in real-time, consistently enabling healthcare providers to enhance their users' and payers' healthcare experiences. The company offers a variety of patent-pending solutions from rehabilitation services to cognitive assessment and training, to pain management. XRHealth works with several world-renowned U.S. healthcare providers, hospitals and rehabilitation centers. Founded in 2016, XRHealth is headquartered in Boston, Massachusetts. For more information, visit https://www.xr.health/.

CONTACT:
DeeDee Rudenstein
267-521-9654
[email protected]

 

 

SOURCE XRHealth


These press releases may also interest you

at 22:16
On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system...

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...



News published on and distributed by: